Patent intelligence · US
US 11883432
Chimeric antigen receptor system with adaptable receptor specificity
Chimeric antigen receptor system with adaptable receptor specificity
Patent details — US 11883432
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 30, 2024
- Expiration
- Jan 25, 2044
- Applicant
- Century Therapeutics, Inc.
- Claims
- 13
- CPC classes
- A61K, A61K40/11, A61K40/31, A61K40/4204
Quick answer
US 11883432 (Chimeric antigen receptor system with adaptable receptor specificity) is held by Century Therapeutics, Inc.. Status: granted. Granted Jan 30, 2024. Expires Jan 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Century Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K40/11, A61K40/31, A61K40/4204, A61P, A61P35/00
More from Century Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12274710
Compound for regulating body weight imbalance, composition thereof and application thereof
granted -
US 12269888
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
granted -
US 12194049
Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection
granted -
US 12084670
Regulating alkaloids
granted -
US 11865155
Plant extract obtained from Morus plant leaves which has an IC50 value to inhibit a-glucosidase I at a concentration of less than 90 uG/ml, compositions containing same, method of extraction and uses thereof
granted -
US 11667924
Increasing levels of nicotinic alkaloids in plants
granted -
US 11661459
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
granted
Frequently asked questions
What is US patent 11883432?
US 11883432 (Chimeric antigen receptor system with adaptable receptor specificity) is held by Century Therapeutics, Inc.. Status: granted. Granted Jan 30, 2024. Expires Jan 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11883432?
Century Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 39 pharmaceutical patents for this assignee.
When does US 11883432 expire?
Our index shows an expiration date of Jan 25, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.